News of Note—GlaxoSmithKline’s R&D fix; Leo-HitGen deal; Stanford I-O pact

Newspapers

> GlaxoSmithKline CEO Emma Walmsley outlined her fix for the company's long-standing pipeline woes. The plan is to give the commercial team a bigger say in pipeline decisions. Article 

> Leo Pharma formed a research collaboration with HitGen. The agreement will see HitGen turn its technology on targets of interest to Leo. Statement 

> Alligator Bioscience expanded its immuno-oncology collaboration with Stanford University. Release